Astek Diagnostics

Astek Diagnostics

Astek Diagnostics

The pilot accuracy progression from 82% to 97% across named institutional partners is the kind of de-risking evidence that makes a seed-stage healthcare deck actually fundable.

The pilot accuracy progression from 82% to 97% across named institutional partners is the kind of de-risking evidence that makes a seed-stage healthcare deck actually fundable.

Company Name

Astek Diagnostics

About Company

Astek Diagnostics is a medtech startup developing the Jiddu system, a point-of-care device that detects bacterial infections and antibiotic sensitivity in under one hour. Their urine-based test has reached 96.97% accuracy across 408 pilot tests conducted with MedStar Health and the University of Maryland.

Astek Diagnostics is a medtech startup developing the Jiddu system, a point-of-care device that detects bacterial infections and antibiotic sensitivity in under one hour. Their urine-based test has reached 96.97% accuracy across 408 pilot tests conducted with MedStar Health and the University of Maryland.

Founded

2020

Year

2023

Stage

Seed

Industry

Healthcare

Website

Pitch Deck:

Pitch Deck Details:

Astek Diagnostics Pitch Deck: A Founder-Level Breakdown

Astek Diagnostics built a 21-slide deck that does something most early-stage decks fail at: it tells a tight problem-solution story without losing the investor in jargon. The UTI diagnostic gap is the anchor. From slide one, the deck makes the pain concrete, with 8.1 million hospital visits, 47% misdiagnoses, and 68,000 annual deaths tied directly to UTI-related sepsis. That's a hook most healthcare decks bury three slides too deep.

The structure moves fast but doesn't skip steps. Problem, solution, technology validation, team, traction, comparable exits. Each section earns its place. The deck is a good case study in how to create a compelling pitch deck without overstuffing slides with text.

What the Deck Gets Right

The deck's biggest strength is how it uses real pilot data to compress investor skepticism early.

  • Accuracy numbers are named by pilot phase: 82%, 95.6%, 96.97%

  • Partners are institutional: University of Maryland, MedStar Health, Johns Hopkins

  • Revenue model is clear: $10K device purchase, $50 per test cartridge

  • IP position is listed with patent numbers, not vague "proprietary technology" claims

  • Exit comps include actual transaction data with revenue multiples ranging from 3.8x to 59.5x

Most seed-stage decks claim traction. This one quantifies it with 408 completed tests and named pilot partners. That's what gets past the first filter. Founders looking to understand what data investors expect in a first pitch deck will find this deck genuinely instructive.

Where Founders Can Learn From the Structure

The deck's visual design is clean but functional, not flashy. That works in its favor for a diagnostics company pitching to serious medtech investors.

  • The "How It Works" section uses a four-step flow that breaks down complex microfluidic science into readable steps

  • The advisory board slide groups advisors by specialty, urology, intensive care, and infectious disease, which signals domain depth without a lengthy bio

  • The comparable transactions slide uses median and mean multiples, giving investors an exit range to anchor valuation conversations

  • The timeline slide is honest about what's completed versus pending, without overselling timelines

One area that stands out as a format choice: the deck uses convertible notes with a BIITC tax incentive for Maryland-based investors. Including that on the investment terms slide, with a direct explanation of the 33% refund, reduces friction for first-time investors. Founders raising early rounds should note how understanding deal structure affects investor decision-making.

This Pitch Deck is taken from bestpitchdeck.

SheetVenture helps founders identify the right investors before they even open a deck, using real-time data from the market's most active private equity database.

FAQ:

Have questions,
We got answers.

Can't find your answer?

Get in touch with our support team, they a re friendly!

How does SheetVenture help founders build better pitch materials?

SheetVenture's private market intelligence platform gives founders access to active investor data so they can target the right VCs before they build the deck. Reaching the wrong investors with a great deck is still a wasted round.

How does the comparable transactions slide help the investment case?

It gives investors a concrete exit range by referencing six actual diagnostic company acquisitions, with purchase prices and revenue multiples from public and private sources. That context anchors the valuation conversation without the founder having to defend a number cold.

What makes the Astek pitch deck stand out from a structural standpoint?

The deck leads with quantified market pain before introducing the product, which keeps investor attention through the solution slides. Real pilot accuracy data, named partners, and IP disclosures are placed where they do the most work.

Built for Founders and Investors

AI-powered insights for founders raising capital and investors seeking high-quality deals.

Find active investors, validate your market, and raise with confidence. Powered by AI and real-time deal data.

Understand your market in real-time.

Filter by stage, sector, and exact geography.

Access 30,000+ verified, daily-updated active

Find active investors, validate your market, and raise with confidence. Powered by AI and real-time deal data.

Understand your market in real-time.

Filter by stage, sector, and exact geography.

Access 30,000+ verified, daily-updated active

Find active investors, validate your market, and raise with confidence. Powered by AI and real-time deal data.

Understand your market in real-time.

Filter by stage, sector, and exact geography.

Access 30,000+ verified, daily-updated active